Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

NCT01965119 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01965119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01965119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2013
Completion date
September 18, 2018
Enrollment
20 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary mediastinal large b-cell lymphoma, relapsed or refractory hodgkin lymphoma